Augmented frontal cortex diacylglycerol levels in Parkinson’s disease and Lewy Body Disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Research from our laboratory, and that of other investigators, has demonstrated augmented levels of diacylglycerols (DAG) in the frontal cortex and plasma of subjects with Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI). We have extended these observations to investigate the frontal cortex of subjects with Parkinson's disease (PD) and Lewy Body Disease (LBD), with and without coexisting pathologic features of AD. METHODS/PRINCIPAL FINDINGS: Utilizing a high-resolution mass spectrometry analytical platform, we clearly demonstrate that DAG levels are significantly increased in the frontal cortex of subjects with PD, LBD with intermediate neocortical AD neuropathology, and in LBD with established neocortical AD neuropathology. In the case of the PD cohort, increases in cortical DAG levels were detected in cases with no neocortical pathology but were greater in subjects with neocortical pathology. These data suggest that DAG changes occur early in the disease processes and are amplified as cortical dysfunction becomes more established. CONCLUSIONS: These findings suggest that altered DAG synthesis/metabolism is a common feature of neurodegenerative diseases, characterized by proteinopathy, that ultimately result in cognitive deficits. With regard to the mechanism responsible for these biochemical alterations, selective decrements in cortical levels of phosphatidylcholines in LBD and PD suggest that augmented degradation and/or decreased synthesis of these structural glycerophospholipids may contribute to increases in the pool size of free DAGs. The observed augmentation of DAG levels may be phospholipase-driven since neuroinflammation is a consistent feature of all disease cohorts. If this conclusion can be validated it would support utilizing DAG levels as a biomarker of the early disease process and the investigation of early intervention with anti-inflammatory agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791
Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer Disease
Chan, R. B., Oliveira, T. G., Cortes, E. P., Honig, L. S., Duff, K. E., Small, S. A., Wenk, M. R., Shui, G., & Di Paolo, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274142 · Cited by 630
Neurodegeneration and Inflammation in Parkinson's disease
Phani, S., Loike, J. D., & Przedborski, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70064-5 · Cited by 263
Bachstetter, A. D., Van Eldik, L. J., Schmitt, F. A., Neltner, J. H., Ighodaro, E. T., Webster, S. J., Patel, E., Abner, E. L., Kryscio, R. J., & Nelson, P. T. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0209-z · Cited by 258
Neuronal dark matter: the emerging role of microRNAs in neurodegeneration
Goodall, E. F., Heath, P. R., Bandmann, O., Kirby, J., & Shaw, P. J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00178 · Cited by 187
Lipidomics of Alzheimer's disease: current status
Wood, P. L. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt103 · Cited by 167
Self-citationZhang, Q.-S., Heng, Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2016.11.002 · Cited by 156
Cited by
Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
Alecu, I., & Bennett, S. A. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00328 · Cited by 258
Marian, O. C., Teo, J. D., Lee, J. Y., Song, H., Kwok, J. B., Landin-Romero, R., Halliday, G., & Don, A. S. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01544-7 · Cited by 50
Cerasuolo, M., Di Meo, I., Auriemma, M. C., Paolisso, G., Papa, M., & Rizzo, M. R. (2024) · Biomolecules · doi:10.3390/biom14111362 · Cited by 47
Kalecký, K., & Bottiglieri, T. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00531-y · Cited by 32
Metadata
- Authors
- Wood, P. L., Tippireddy, S., Feriante, J., & Woltjer, R. L.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-03-07
- Volume
- 13
- Issue
- 3
- Pages
- e0191815
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2789783533
- Cited by
- 74
- References
- 8
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Augmented frontal cortex diacylglycerol levels in Parkinson’s disease and Lewy Body Disease. https://app.cochat.ai/papers/10.1371/journal.pone.0191815
- The paper
- Wood, P. L., Tippireddy, S., Feriante, J., & Woltjer, R. L. (2018). Augmented frontal cortex diacylglycerol levels in Parkinson’s disease and Lewy Body Disease. PLOS ONE. https://doi.org/10.1371/journal.pone.0191815
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.